Chembio Diagnostics

Chembio Diagnostics

Chembio Diagnostics is a New York-based company specializing in detecting disease in humans and animals using biomarkers in blood.

Chembio Diagnostics is a New York-based company specializing in detecting disease in humans and animals using biomarkers in blood. The company was founded in 1986.

Technology

Chembio Diagnostics offers rapid, point of care testing for a range of diseases. Its testing platform is based on chromatographic immunoassay technology which the company calls its Dual Path Platform (DPP). The company filed a patent for its DPP technology in 2005 and was granted the patent in 2007. Chembio Diagnostics holds several other patents related to its DPP technology.

COVID-19 Response

On March 31, Chembio Diagnostics announced the U.S. launch of its rapid serological tests for COVID-19 antibodies. The company says its tests can detect IgM and IgG antibodies and can deliver results in 15 minutes.

Timeline

May 14, 1999

Chembio Diagnostics was founded.

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Chembio launches rapid COVID-19 blood test; shares up 54% premarket

Douglas W. House

Web

April 1, 2020

Chembio, Molecule Holdings launch fingerstick COVID-19 tests - MassDevice

Web

April 1, 2020

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title0
Author0
Date0
Publisher0
Description0
BioSpace Editorial Staff
May 18, 2020
BioSpace
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 18, 2020.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.